Literature DB >> 8689617

Essential thrombocythemia with BCR/ABL rearrangement.

Y L Kwong1, E K Chiu, R H Liang, V Chan, T K Chan.   

Abstract

Essential thrombocythemia (ET) was diagnosed clinically in three patients Karyotypic analysis and reverse transcription polymerase chain reaction for the bcr-abl chimeric transcript showed that two were Philadelphia chromosome (Ph) positive, bcr-abl positive, whereas the third was Ph negative, bcr-abl positive. The first patient received an allogeneic bone marrow transplantation but relapsed as localized blastic transformation, thus behaving similarly to chronic myeloid leukemia (CML). However, the other patients showed clinical courses more in keeping with ET. Essential thrombocythemia with BCR rearrangements may resemble CML but there are clinical differences. These may be due to genetic changes in addition to the BCR rearrangement.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8689617     DOI: 10.1016/0165-4608(94)00108-1

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  A case of chronic myeloid leukemia with features of essential thrombocythemia in peripheral blood and bone marrow.

Authors:  Young Jae Byun; Byeong-Bae Park; Eun Sung Lee; Kyung Soo Choi; Dae Sung Lee
Journal:  Blood Res       Date:  2014-06-25

2.  Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.

Authors:  Gholamreza Toogeh; Shirin Ferdowsi; Fatemeh Naadali; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Reza Shirkoohi; Seyed H Ghaffari
Journal:  Med Oncol       Date:  2010-05-25       Impact factor: 3.064

3.  Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

Authors:  Yoo Jin Lee; Joon Ho Moon; Ho Cheol Shin; Jong Won Seo; Seo Ae Han; Sang Kyeong Seo; Sang Kyun Sohn
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.